Skip to main content
main-content
Erschienen in: Zeitschrift für Rheumatologie 2/2018

03.07.2018 | Rheumatoide Arthritis | Leitlinien

S2e-Leitlinie: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten

verfasst von: Prof. Dr. med. C. Fiehn, J. Holle, C. Iking-Konert, J. Leipe, C. Weseloh, M. Frerix, R. Alten, F. Behrens, C. Baerwald, J. Braun, H. Burkhardt, G. Burmester, J. Detert, M. Gaubitz, A. Gause, E. Gromnica-Ihle, H. Kellner, A. Krause, J. Kuipers, H.-M. Lorenz, U. Müller-Ladner, M. Nothacker, H. Nüsslein, A. Rubbert-Roth, M. Schneider, H. Schulze-Koops, S. Seitz, H. Sitter, C. Specker, H.-P. Tony, S. Wassenberg, J. Wollenhaupt, K. Krüger

Erschienen in: Zeitschrift für Rheumatologie | Sonderheft 2/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Medikamentöse Therapiestrategien zur Behandlung der rheumatoiden Arthritis sind entscheidend für den Langzeitverlauf. Sie dienen dem Ziel, durch frühe und konsequente Unterdrückung der Entzündung Gelenkzerstörung zu verhindern und damit die Funktion zu erhalten.

Ziel der Arbeit

Erarbeitung eines Konsenses für evidenzbasierte Empfehlungen zur Behandlung der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten in Deutschland.

Methoden

Nach einer systematischen Literatursuche wurde ein strukturierter Konsensprozess durchgeführt.

Ergebnisse

Sechs übergeordnete Prinzipien und 10 Empfehlungen fassen die Ergebnisse des Konsensprozesses zusammen. Verschiedene Punkte sind gegenüber der Fassung von 2012 neu, so die differenzierte Anpassung des Therapieregimes nach Zeitpunkt und Ausmaß des Ansprechens, das Therapieziel Remission gemessen mithilfe des simplified disease activity index (SDAI) wie auch der potentielle Einsatz zielgerichteter synthetischer DMARDs (tsDMARDs), der JAK-Inhibitoren sowie Empfehlungen zur Deeskalation nach dem Erreichen einer anhaltenden Remission. Wie bisher steht Methotrexat (MTX) im Mittelpunkt der Therapie zu Beginn und als Kombinationspartner im weiteren Verlauf. Die Kombination mehrerer konventioneller synthetischer DMARDs, oder, bei ungünstigen prognostischen Faktoren, der Einsatz von biologischen oder tsDMARDs kommen nach dem Algorithmus bei nicht ausreichendem Ansprechen auf Methotrexat zur Anwendung. Empfehlungen für die Deeskalation der Therapie mit Glukokortikoiden und konsekutiv gegebenenfalls auch DMARDs geben Hilfe für den Umgang mit Patienten, die eine anhaltende Remission erreicht haben.

Zusammenfassung

Die neue S2-Leitlinie gibt Empfehlungen für die Therapie der RA nach dem Prinzip des „Treat-to-Target“ (T2T) mit etablierten und neuen krankheitsmodifizierenden Medikamenten (DMARDs), einschließlich der Biologika und JAK-Inhibitoren und macht Vorschläge zur Deeskalation nach Erreichen einer anhaltenden Remission.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Albrecht K, Callhoff J, Edelmann E et al (2016) Clinical remission in rheumatoid arthritis. Data from the early arthritis cohort study CAPEA. Z Rheumatol 75:90–96 PubMed Albrecht K, Callhoff J, Edelmann E et al (2016) Clinical remission in rheumatoid arthritis. Data from the early arthritis cohort study CAPEA. Z Rheumatol 75:90–96 PubMed
2.
Zurück zum Zitat Albrecht K, Huscher D, Eidner T et al (2017) Medical treatment of rheumatoid arthritis in 2014 : current data from the German collaborative arthritis centers. Z Rheumatol 76:50–57 PubMed Albrecht K, Huscher D, Eidner T et al (2017) Medical treatment of rheumatoid arthritis in 2014 : current data from the German collaborative arthritis centers. Z Rheumatol 76:50–57 PubMed
3.
Zurück zum Zitat Aletaha D, Alasti F, Smolen JS (2016) Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3‑month time point. Ann Rheum Dis 75:1479–1485 PubMed Aletaha D, Alasti F, Smolen JS (2016) Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3‑month time point. Ann Rheum Dis 75:1479–1485 PubMed
4.
Zurück zum Zitat Aletaha D, Funovits J, Keystone EC et al (2007) Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 56:3226–3235 PubMed Aletaha D, Funovits J, Keystone EC et al (2007) Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 56:3226–3235 PubMed
5.
Zurück zum Zitat Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588 PubMed Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588 PubMed
6.
Zurück zum Zitat Alivernini S, Peluso G, Fedele AL et al (2016) Tapering and discontinuation of TNF-alpha blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. Arthritis Res Ther 18:39 PubMedPubMedCentral Alivernini S, Peluso G, Fedele AL et al (2016) Tapering and discontinuation of TNF-alpha blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. Arthritis Res Ther 18:39 PubMedPubMedCentral
7.
Zurück zum Zitat Andersson ML, Bergman S, Soderlin MK (2012) The effect of stopping smoking on disease activity in rheumatoid arthritis (RA). Data from BARFOT, a multicenter study of early RA. Open Rheumatol J 6:303–309 PubMedPubMedCentral Andersson ML, Bergman S, Soderlin MK (2012) The effect of stopping smoking on disease activity in rheumatoid arthritis (RA). Data from BARFOT, a multicenter study of early RA. Open Rheumatol J 6:303–309 PubMedPubMedCentral
8.
Zurück zum Zitat Barnabe C, Martin BJ, Ghali WA (2011) Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 63:522–529 Barnabe C, Martin BJ, Ghali WA (2011) Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 63:522–529
9.
Zurück zum Zitat Braun J, Kastner P, Flaxenberg P et al (2008) Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 58:73–81 PubMed Braun J, Kastner P, Flaxenberg P et al (2008) Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 58:73–81 PubMed
10.
Zurück zum Zitat Burmester GR, Blanco R, Charles-Schoeman C et al (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:451–460 PubMed Burmester GR, Blanco R, Charles-Schoeman C et al (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:451–460 PubMed
11.
Zurück zum Zitat Burmester GR, Kivitz AJ, Kupper H et al (2015) Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 74:1037–1044 PubMed Burmester GR, Kivitz AJ, Kupper H et al (2015) Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 74:1037–1044 PubMed
12.
Zurück zum Zitat Burmester GR, Lin Y, Patel R et al (2017) Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 76:840–847 PubMed Burmester GR, Lin Y, Patel R et al (2017) Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 76:840–847 PubMed
13.
Zurück zum Zitat Burmester GR, Rigby WF, Van Vollenhoven RF et al (2016) Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis 75:1081–1091 PubMed Burmester GR, Rigby WF, Van Vollenhoven RF et al (2016) Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis 75:1081–1091 PubMed
14.
Zurück zum Zitat Bykerk VP, Lie E, Bartlett SJ et al (2014) Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare workshop. J Rheumatol 41:799–809 PubMedPubMedCentral Bykerk VP, Lie E, Bartlett SJ et al (2014) Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare workshop. J Rheumatol 41:799–809 PubMedPubMedCentral
15.
Zurück zum Zitat Chatzidionysiou K, Emamikia S, Nam J et al (2017) Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 76:1102–1107 PubMed Chatzidionysiou K, Emamikia S, Nam J et al (2017) Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 76:1102–1107 PubMed
16.
Zurück zum Zitat Combe B, Landewe R, Daien CI et al (2017) 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 76:948–959 PubMed Combe B, Landewe R, Daien CI et al (2017) 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 76:948–959 PubMed
17.
Zurück zum Zitat Curtis JR, Luijtens K, Kavanaugh A (2012) Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year. Arthritis Care Res (hoboken) 64:658–667 Curtis JR, Luijtens K, Kavanaugh A (2012) Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year. Arthritis Care Res (hoboken) 64:658–667
18.
Zurück zum Zitat Dale J, Purves D, Mcconnachie A et al (2014) Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care Res (hoboken) 66:19–26 Dale J, Purves D, Mcconnachie A et al (2014) Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care Res (hoboken) 66:19–26
19.
Zurück zum Zitat De Jong PH, Hazes JM, Han HK et al (2014) Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1‑year data of the tREACH trial. Ann Rheum Dis 73:1331–1339 PubMed De Jong PH, Hazes JM, Han HK et al (2014) Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1‑year data of the tREACH trial. Ann Rheum Dis 73:1331–1339 PubMed
20.
Zurück zum Zitat Den Uyl D, Ter Wee M, Boers M et al (2014) A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis 73:1071–1078 Den Uyl D, Ter Wee M, Boers M et al (2014) A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis 73:1071–1078
21.
Zurück zum Zitat Dougados M, Huizinga TW, Choy EH et al (2015) Evaluation of the disease activity score in twenty-eight joints-based flare definitions in rheumatoid arthritis: data from a three-year clinical trial. Arthritis Care Res (hoboken) 67:1762–1766 Dougados M, Huizinga TW, Choy EH et al (2015) Evaluation of the disease activity score in twenty-eight joints-based flare definitions in rheumatoid arthritis: data from a three-year clinical trial. Arthritis Care Res (hoboken) 67:1762–1766
22.
Zurück zum Zitat Dougados M, Kissel K, Conaghan PG et al (2014) Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 73:803–809 PubMed Dougados M, Kissel K, Conaghan PG et al (2014) Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 73:803–809 PubMed
23.
Zurück zum Zitat Dougados M, Van Der Heijde D, Chen YC et al (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76:88–95 PubMed Dougados M, Van Der Heijde D, Chen YC et al (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76:88–95 PubMed
24.
Zurück zum Zitat Duru N, Van Der Goes MC, Jacobs JW et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72:1905–1913 PubMed Duru N, Van Der Goes MC, Jacobs JW et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72:1905–1913 PubMed
25.
Zurück zum Zitat Emery P, Bingham CO 3rd, Burmester GR et al (2017) Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1‑year results from C‑EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis 76:96–104 PubMed Emery P, Bingham CO 3rd, Burmester GR et al (2017) Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1‑year results from C‑EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis 76:96–104 PubMed
26.
Zurück zum Zitat Emery P, Burmester GR, Bykerk VP et al (2015) Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74:19–26 PubMed Emery P, Burmester GR, Bykerk VP et al (2015) Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74:19–26 PubMed
27.
Zurück zum Zitat Emery P, Gottenberg JE, Rubbert-Roth A et al (2015) Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 74:979–984 PubMed Emery P, Gottenberg JE, Rubbert-Roth A et al (2015) Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 74:979–984 PubMed
28.
Zurück zum Zitat Emery P, Hammoudeh M, Fitzgerald O et al (2014) Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 371:1781–1792 PubMed Emery P, Hammoudeh M, Fitzgerald O et al (2014) Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 371:1781–1792 PubMed
29.
Zurück zum Zitat Fautrel B, Pham T, Alfaiate T et al (2016) Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Ann Rheum Dis 75:59–67 PubMed Fautrel B, Pham T, Alfaiate T et al (2016) Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Ann Rheum Dis 75:59–67 PubMed
30.
Zurück zum Zitat Felson DT, Smolen JS, Wells G et al (2011) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404–413 PubMed Felson DT, Smolen JS, Wells G et al (2011) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404–413 PubMed
31.
Zurück zum Zitat Fiehn C, Belke-Voss E, Krause D et al (2013) Improved radiological outcome of rheumatoid arthritis: the importance of early treatment with methotrexate in the era of biological drugs. Clin Rheumatol 32:1735–1742 PubMed Fiehn C, Belke-Voss E, Krause D et al (2013) Improved radiological outcome of rheumatoid arthritis: the importance of early treatment with methotrexate in the era of biological drugs. Clin Rheumatol 32:1735–1742 PubMed
32.
Zurück zum Zitat Fiehn C, Herzer P, Holle J et al (2016) Klug entscheiden in der Rheumatologie. Dtsch Arztebl 113:A-1154 (B-1939/C-1953) Fiehn C, Herzer P, Holle J et al (2016) Klug entscheiden in der Rheumatologie. Dtsch Arztebl 113:A-1154 (B-1939/C-1953)
33.
Zurück zum Zitat Finckh A, Choi HK, Wolfe F (2006) Progression of radiographic joint damage in different eras: trends towards milder disease in rheumatoid arthritis are attributable to improved treatment. Ann Rheum Dis 65:1192–1197 PubMedPubMedCentral Finckh A, Choi HK, Wolfe F (2006) Progression of radiographic joint damage in different eras: trends towards milder disease in rheumatoid arthritis are attributable to improved treatment. Ann Rheum Dis 65:1192–1197 PubMedPubMedCentral
34.
Zurück zum Zitat Fleischmann R, Kremer J, Cush J et al (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367:495–507 PubMed Fleischmann R, Kremer J, Cush J et al (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367:495–507 PubMed
35.
Zurück zum Zitat Fleischmann R, Mysler E, Hall S et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 390:457–468 PubMed Fleischmann R, Mysler E, Hall S et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 390:457–468 PubMed
36.
Zurück zum Zitat Fleischmann R, Schiff M, Van Der Heijde D et al (2017) Baricitinib, Methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69:506–517 PubMedPubMedCentral Fleischmann R, Schiff M, Van Der Heijde D et al (2017) Baricitinib, Methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69:506–517 PubMedPubMedCentral
37.
Zurück zum Zitat Gabay C, Emery P, Van Vollenhoven R et al (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381:1541–1550 PubMed Gabay C, Emery P, Van Vollenhoven R et al (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381:1541–1550 PubMed
38.
Zurück zum Zitat Genovese MC, Kremer J, Zamani O et al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374:1243–1252 PubMed Genovese MC, Kremer J, Zamani O et al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374:1243–1252 PubMed
39.
Zurück zum Zitat Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM et al (2016) Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol 68:1810–1817 PubMed Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM et al (2016) Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol 68:1810–1817 PubMed
40.
Zurück zum Zitat Glintborg B, Sorensen IJ, Loft AG et al (2017) A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1‑year clinical outcomes from the DANBIO registry. Ann Rheum Dis 76:1426–1431 PubMed Glintborg B, Sorensen IJ, Loft AG et al (2017) A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1‑year clinical outcomes from the DANBIO registry. Ann Rheum Dis 76:1426–1431 PubMed
41.
Zurück zum Zitat Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146:406–415 PubMed Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146:406–415 PubMed
42.
Zurück zum Zitat Golicki D, Newada M, Lis J et al (2012) Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials. Pol Arch Med Wewn 122:22–32 PubMed Golicki D, Newada M, Lis J et al (2012) Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials. Pol Arch Med Wewn 122:22–32 PubMed
43.
Zurück zum Zitat Gottenberg JE, Brocq O, Perdriger A et al (2016) Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA 316:1172–1180 PubMed Gottenberg JE, Brocq O, Perdriger A et al (2016) Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA 316:1172–1180 PubMed
44.
Zurück zum Zitat Gottenberg JE, Courvoisier DS, Hernandez MV et al (2016) Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of Abatacept: results from the Pan-European Registry Analysis. Arthritis Rheumatol 68:1346–1352 PubMed Gottenberg JE, Courvoisier DS, Hernandez MV et al (2016) Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of Abatacept: results from the Pan-European Registry Analysis. Arthritis Rheumatol 68:1346–1352 PubMed
46.
Zurück zum Zitat Haavardsholm EA, Aga AB, Olsen IC et al (2016) Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ 354:i4205 PubMedPubMedCentral Haavardsholm EA, Aga AB, Olsen IC et al (2016) Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ 354:i4205 PubMedPubMedCentral
47.
Zurück zum Zitat Harrold LR, Reed GW, Kremer JM et al (2015) The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis 74:430–436 PubMed Harrold LR, Reed GW, Kremer JM et al (2015) The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis 74:430–436 PubMed
48.
Zurück zum Zitat Harrold LR, Reed GW, Solomon DH et al (2016) Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. Arthritis Res Ther 18:280 PubMedPubMedCentral Harrold LR, Reed GW, Solomon DH et al (2016) Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. Arthritis Res Ther 18:280 PubMedPubMedCentral
49.
Zurück zum Zitat Haschka J, Englbrecht M, Hueber AJ et al (2016) Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis 75:45–51 PubMed Haschka J, Englbrecht M, Hueber AJ et al (2016) Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis 75:45–51 PubMed
50.
Zurück zum Zitat Hazlewood GS, Barnabe C, Tomlinson G et al (2016) Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ 353:i1777 PubMedPubMedCentral Hazlewood GS, Barnabe C, Tomlinson G et al (2016) Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ 353:i1777 PubMedPubMedCentral
51.
Zurück zum Zitat Hazlewood GS, Thorne JC, Pope JE et al (2016) The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis 75:1003–1008 PubMed Hazlewood GS, Thorne JC, Pope JE et al (2016) The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis 75:1003–1008 PubMed
52.
Zurück zum Zitat Heimans L, Wevers-De Boer KV, Visser K et al (2014) A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis 73:1356–1361 PubMed Heimans L, Wevers-De Boer KV, Visser K et al (2014) A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis 73:1356–1361 PubMed
53.
Zurück zum Zitat Hetland ML, Horslev-Petersen K (2012) The CIMESTRA study: intra-articular glucocorticosteroids and synthetic DMARDs in a treat-to-target strategy in early rheumatoid arhtritis. Clin Exp Rheumatol 30:S44–49 PubMed Hetland ML, Horslev-Petersen K (2012) The CIMESTRA study: intra-articular glucocorticosteroids and synthetic DMARDs in a treat-to-target strategy in early rheumatoid arhtritis. Clin Exp Rheumatol 30:S44–49 PubMed
54.
Zurück zum Zitat Hoes JN, Jacobs JW, Boers M et al (2007) EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66:1560–1567 PubMedPubMedCentral Hoes JN, Jacobs JW, Boers M et al (2007) EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66:1560–1567 PubMedPubMedCentral
55.
Zurück zum Zitat Huizinga TW, Conaghan PG, Martin-Mola E et al (2015) Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 74:35–43 PubMed Huizinga TW, Conaghan PG, Martin-Mola E et al (2015) Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 74:35–43 PubMed
56.
Zurück zum Zitat Huscher D, Sengler C, Gromnica-Ihle E et al (2013) Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account. Clin Exp Rheumatol 31:256–262 PubMed Huscher D, Sengler C, Gromnica-Ihle E et al (2013) Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account. Clin Exp Rheumatol 31:256–262 PubMed
57.
Zurück zum Zitat Isaacs JD, Cohen SB, Emery P et al (2013) Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 72:329–336 PubMed Isaacs JD, Cohen SB, Emery P et al (2013) Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 72:329–336 PubMed
58.
Zurück zum Zitat Iwamoto T, Ikeda K, Hosokawa J et al (2014) Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation. Arthritis Care Res (Hoboken) 66:1576–1581 Iwamoto T, Ikeda K, Hosokawa J et al (2014) Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation. Arthritis Care Res (Hoboken) 66:1576–1581
59.
Zurück zum Zitat Kaneko Y, Atsumi T, Tanaka Y et al (2016) Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis 75:1917–1923 PubMed Kaneko Y, Atsumi T, Tanaka Y et al (2016) Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis 75:1917–1923 PubMed
61.
Zurück zum Zitat Keystone EC, Pope JE, Thorne JC et al (2016) Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis. Rheumatology (Oxford) 55:327–334 Keystone EC, Pope JE, Thorne JC et al (2016) Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis. Rheumatology (Oxford) 55:327–334
62.
Zurück zum Zitat Kiely P, Walsh D, Williams R et al (2011) Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity—the early RA network (ERAN). Rheumatology (Oxford) 50:926–931 Kiely P, Walsh D, Williams R et al (2011) Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity—the early RA network (ERAN). Rheumatology (Oxford) 50:926–931
63.
Zurück zum Zitat Klarenbeek NB, Guler-Yuksel M, Van Der Kooij SM et al (2011) The impact of four dynamic, goal-steered treatment strategies on the 5‑year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 70:1039–1046 PubMed Klarenbeek NB, Guler-Yuksel M, Van Der Kooij SM et al (2011) The impact of four dynamic, goal-steered treatment strategies on the 5‑year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 70:1039–1046 PubMed
64.
Zurück zum Zitat Kremer J, Li ZG, Hall S et al (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159:253–261 PubMed Kremer J, Li ZG, Hall S et al (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159:253–261 PubMed
65.
Zurück zum Zitat Kruger K, Wollenhaupt J, Albrecht K et al (2012) German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm. Z Rheumatol 71:592–603 PubMed Kruger K, Wollenhaupt J, Albrecht K et al (2012) German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm. Z Rheumatol 71:592–603 PubMed
66.
Zurück zum Zitat Lee EB, Fleischmann R, Hall S et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377–2386 PubMed Lee EB, Fleischmann R, Hall S et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377–2386 PubMed
67.
Zurück zum Zitat Li R, Zhao JX, Su Y et al (2016) High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): a multicenter randomized clinical trial. Medicine (Baltimore) 95:e3968 Li R, Zhao JX, Su Y et al (2016) High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): a multicenter randomized clinical trial. Medicine (Baltimore) 95:e3968
68.
Zurück zum Zitat Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 52:53–61 Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 52:53–61
69.
Zurück zum Zitat Listing J, Kekow J, Manger B et al (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab. Ann Rheum Dis 74:415–421 PubMed Listing J, Kekow J, Manger B et al (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab. Ann Rheum Dis 74:415–421 PubMed
70.
Zurück zum Zitat Lofland JH, Johnson PT, Ingham MP et al (2017) Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs. Patient Prefer Adherence 11:947–958 PubMedPubMedCentral Lofland JH, Johnson PT, Ingham MP et al (2017) Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs. Patient Prefer Adherence 11:947–958 PubMedPubMedCentral
72.
Zurück zum Zitat Lupoli R, Pizzicato P, Scalera A et al (2016) Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther 18:297 PubMedPubMedCentral Lupoli R, Pizzicato P, Scalera A et al (2016) Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther 18:297 PubMedPubMedCentral
73.
Zurück zum Zitat Manders SH, Kievit W, Jansen TL et al (2016) Effectiveness of tumor necrosis factor inhibitors in combination with various csDMARD in the treatment of rheumatoid arthritis: data from the DREAM registry. J Rheumatol 43:1787–1794 PubMed Manders SH, Kievit W, Jansen TL et al (2016) Effectiveness of tumor necrosis factor inhibitors in combination with various csDMARD in the treatment of rheumatoid arthritis: data from the DREAM registry. J Rheumatol 43:1787–1794 PubMed
74.
Zurück zum Zitat Mandl P, Balint PV, Brault Y et al (2013) Clinical and ultrasound-based composite disease activity indices in rheumatoid arthritis: results from a multicenter, randomized study. Arthritis Care Res (hoboken) 65:879–887 Mandl P, Balint PV, Brault Y et al (2013) Clinical and ultrasound-based composite disease activity indices in rheumatoid arthritis: results from a multicenter, randomized study. Arthritis Care Res (hoboken) 65:879–887
75.
Zurück zum Zitat Maneiro JR, Salgado E, Gomez-Reino JJ (2013) Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis. Jama Intern Med 173:1416–1428 PubMed Maneiro JR, Salgado E, Gomez-Reino JJ (2013) Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis. Jama Intern Med 173:1416–1428 PubMed
76.
Zurück zum Zitat Mouterde G, Baillet A, Gaujoux-Viala C et al (2011) Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 78:587–592 PubMed Mouterde G, Baillet A, Gaujoux-Viala C et al (2011) Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 78:587–592 PubMed
77.
Zurück zum Zitat Nam JL, Takase-Minegishi K, Ramiro S et al (2017) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 76:1113–1136 PubMed Nam JL, Takase-Minegishi K, Ramiro S et al (2017) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 76:1113–1136 PubMed
78.
Zurück zum Zitat Nam JL, Villeneuve E, Hensor EM et al (2014) Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 73:75–85 PubMed Nam JL, Villeneuve E, Hensor EM et al (2014) Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 73:75–85 PubMed
79.
Zurück zum Zitat Naredo E, Valor L, De La Torre I et al (2015) Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis. Rheumatology (Oxford) 54:1408–1414 Naredo E, Valor L, De La Torre I et al (2015) Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis. Rheumatology (Oxford) 54:1408–1414
80.
Zurück zum Zitat Ornbjerg LM, Ostergaard M, Boyesen P et al (2014) Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry. J Rheumatol 41:2352–2360 PubMed Ornbjerg LM, Ostergaard M, Boyesen P et al (2014) Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry. J Rheumatol 41:2352–2360 PubMed
81.
Zurück zum Zitat Pasma A, Hazes JM, Busschbach JJ et al (2017) Psychosocial predictors of DMARD adherence in the first three months of treatment for early arthritis. Patient Educ Couns 100:126–132 PubMed Pasma A, Hazes JM, Busschbach JJ et al (2017) Psychosocial predictors of DMARD adherence in the first three months of treatment for early arthritis. Patient Educ Couns 100:126–132 PubMed
82.
Zurück zum Zitat Ramiro S, Sepriano A, Chatzidionysiou K et al (2017) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 76:1101–1136 PubMed Ramiro S, Sepriano A, Chatzidionysiou K et al (2017) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 76:1101–1136 PubMed
83.
Zurück zum Zitat Rech J, Hueber AJ, Finzel S et al (2016) Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann Rheum Dis 75:1637–1644 PubMed Rech J, Hueber AJ, Finzel S et al (2016) Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann Rheum Dis 75:1637–1644 PubMed
84.
Zurück zum Zitat Rezaei H, Saevarsdottir S, Forslind K et al (2012) In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2‑year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis 71:186–191 PubMed Rezaei H, Saevarsdottir S, Forslind K et al (2012) In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2‑year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis 71:186–191 PubMed
85.
Zurück zum Zitat Saevarsdottir S, Rezaei H, Geborek P et al (2015) Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis 74:1509–1514 PubMed Saevarsdottir S, Rezaei H, Geborek P et al (2015) Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis 74:1509–1514 PubMed
86.
Zurück zum Zitat Saevarsdottir S, Wedren S, Seddighzadeh M et al (2011) Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 63:26–36 PubMed Saevarsdottir S, Wedren S, Seddighzadeh M et al (2011) Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 63:26–36 PubMed
87.
Zurück zum Zitat Schiff MH, Jaffe JS, Freundlich B (2014) Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥ 15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 73:1549–1551 PubMed Schiff MH, Jaffe JS, Freundlich B (2014) Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥ 15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 73:1549–1551 PubMed
90.
Zurück zum Zitat Singh JA, Saag KG, Bridges SL Jr. et al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68:1–26 PubMed Singh JA, Saag KG, Bridges SL Jr. et al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68:1–26 PubMed
91.
Zurück zum Zitat Smolen JS, Aletaha D (2015) Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 11:276–289 PubMed Smolen JS, Aletaha D (2015) Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 11:276–289 PubMed
92.
Zurück zum Zitat Smolen JS, Breedveld FC, Burmester GR et al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3–15 PubMed Smolen JS, Breedveld FC, Burmester GR et al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3–15 PubMed
93.
Zurück zum Zitat Smolen JS, Burmester GR, Combe B et al (2016) Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2‑year efficacy and safety results from the randomised EXXELERATE study. Lancet 388:2763–2774 PubMed Smolen JS, Burmester GR, Combe B et al (2016) Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2‑year efficacy and safety results from the randomised EXXELERATE study. Lancet 388:2763–2774 PubMed
94.
Zurück zum Zitat Smolen JS, Han C, Van Der Heijde DM et al (2009) Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 68:823–827 PubMed Smolen JS, Han C, Van Der Heijde DM et al (2009) Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 68:823–827 PubMed
95.
Zurück zum Zitat Smolen JS, Kalden JR, Scott DL et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353:259–266 PubMed Smolen JS, Kalden JR, Scott DL et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353:259–266 PubMed
96.
Zurück zum Zitat Smolen JS, Kay J, Doyle MK et al (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374:210–221 PubMed Smolen JS, Kay J, Doyle MK et al (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374:210–221 PubMed
97.
Zurück zum Zitat Smolen JS, Landewe R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977 PubMed Smolen JS, Landewe R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977 PubMed
98.
Zurück zum Zitat Smolen JS, Nash P, Durez P et al (2013) Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 381:918–929 PubMed Smolen JS, Nash P, Durez P et al (2013) Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 381:918–929 PubMed
99.
Zurück zum Zitat Smolen JS, Van Der Heijde DM, Clair StEW et al (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54:702–710 PubMed Smolen JS, Van Der Heijde DM, Clair StEW et al (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54:702–710 PubMed
100.
Zurück zum Zitat Smolen JS, Wollenhaupt J, Gomez-Reino JJ et al (2015) Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to gauge remission and joint damage progression in methotrexate (MTX)-naive patients with early erosive rheumatoid arthritis (AGREE). Arthritis Res Ther 17:157 PubMedPubMedCentral Smolen JS, Wollenhaupt J, Gomez-Reino JJ et al (2015) Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to gauge remission and joint damage progression in methotrexate (MTX)-naive patients with early erosive rheumatoid arthritis (AGREE). Arthritis Res Ther 17:157 PubMedPubMedCentral
101.
Zurück zum Zitat Sokolove J, Schiff M, Fleischmann R et al (2016) Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2‑year results from the AMPLE trial. Ann Rheum Dis 75:709–714 PubMed Sokolove J, Schiff M, Fleischmann R et al (2016) Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2‑year results from the AMPLE trial. Ann Rheum Dis 75:709–714 PubMed
102.
Zurück zum Zitat Sparks JA, Halperin F, Karlson JC et al (2015) Impact of bariatric surgery on patients with rheumatoid arthritis. Arthritis Care Res (hoboken) 67:1619–1626 Sparks JA, Halperin F, Karlson JC et al (2015) Impact of bariatric surgery on patients with rheumatoid arthritis. Arthritis Care Res (hoboken) 67:1619–1626
103.
Zurück zum Zitat Stoffer MA, Schoels MM, Smolen JS et al (2016) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis 75:16–22 PubMed Stoffer MA, Schoels MM, Smolen JS et al (2016) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis 75:16–22 PubMed
104.
Zurück zum Zitat Stoffer MA, Smolen JS, Woolf A et al (2014) Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. Ann Rheum Dis 73:902–905 PubMed Stoffer MA, Smolen JS, Woolf A et al (2014) Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. Ann Rheum Dis 73:902–905 PubMed
105.
Zurück zum Zitat Strangfeld A, Eveslage M, Schneider M et al (2011) Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70:1914–1920 PubMed Strangfeld A, Eveslage M, Schneider M et al (2011) Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70:1914–1920 PubMed
106.
Zurück zum Zitat Strehl C, Bijlsma JW, De Wit M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis 75:952–957 PubMed Strehl C, Bijlsma JW, De Wit M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis 75:952–957 PubMed
107.
Zurück zum Zitat Tanaka Y, Hirata S, Kubo S et al (2015) Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1‑year outcome of the HONOR study. Ann Rheum Dis 74:389–395 PubMed Tanaka Y, Hirata S, Kubo S et al (2015) Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1‑year outcome of the HONOR study. Ann Rheum Dis 74:389–395 PubMed
108.
Zurück zum Zitat Taylor PC, Keystone EC, Van Der Heijde D et al (2017) Baricitinib versus placebo or Adalimumab in rheumatoid arthritis. N Engl J Med 376:652–662 PubMed Taylor PC, Keystone EC, Van Der Heijde D et al (2017) Baricitinib versus placebo or Adalimumab in rheumatoid arthritis. N Engl J Med 376:652–662 PubMed
109.
Zurück zum Zitat Ter Wee MM, Lems WF, Usan H et al (2012) The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review. Ann Rheum Dis 71:161–171 PubMed Ter Wee MM, Lems WF, Usan H et al (2012) The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review. Ann Rheum Dis 71:161–171 PubMed
110.
Zurück zum Zitat Van Aken J, Heimans L, Gillet-Van Dongen H et al (2014) Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). Ann Rheum Dis 73:396–400 PubMed Van Aken J, Heimans L, Gillet-Van Dongen H et al (2014) Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). Ann Rheum Dis 73:396–400 PubMed
111.
Zurück zum Zitat Van Der Heijde D, Aletaha D, Carmona L et al (2015) 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 74:8–13 Van Der Heijde D, Aletaha D, Carmona L et al (2015) 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 74:8–13
112.
Zurück zum Zitat Van Der Heijde D, Keystone EC, Curtis JR et al (2012) Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. J Rheumatol 39:1326–1333 Van Der Heijde D, Keystone EC, Curtis JR et al (2012) Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. J Rheumatol 39:1326–1333
113.
Zurück zum Zitat Van Der Heijde D, Tanaka Y, Fleischmann R et al (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65:559–570 Van Der Heijde D, Tanaka Y, Fleischmann R et al (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65:559–570
114.
Zurück zum Zitat Van Der Heijde DM, Van Riel PL, Van Leeuwen MA et al (1992) Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 31:519–525 Van Der Heijde DM, Van Riel PL, Van Leeuwen MA et al (1992) Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 31:519–525
115.
Zurück zum Zitat Van Der Maas A, Kievit W, Van Den Bemt BJ et al (2012) Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 71:1849–1854 Van Der Maas A, Kievit W, Van Den Bemt BJ et al (2012) Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 71:1849–1854
116.
Zurück zum Zitat Van Dongen H, Van Aken J, Lard LR et al (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56:1424–1432 PubMed Van Dongen H, Van Aken J, Lard LR et al (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56:1424–1432 PubMed
117.
Zurück zum Zitat Van Gestel AM, Prevoo ML, Van ’T Hof MA et al (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39:34–40 PubMed Van Gestel AM, Prevoo ML, Van ’T Hof MA et al (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39:34–40 PubMed
118.
Zurück zum Zitat Van Herwaarden N, Van Der Maas A, Minten MJ et al (2015) Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 350:h1389 PubMedPubMedCentral Van Herwaarden N, Van Der Maas A, Minten MJ et al (2015) Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 350:h1389 PubMedPubMedCentral
119.
Zurück zum Zitat Van Leeuwen MA, Van Rijswijk MH, Sluiter WJ et al (1997) Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 24:20–27 PubMed Van Leeuwen MA, Van Rijswijk MH, Sluiter WJ et al (1997) Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 24:20–27 PubMed
120.
Zurück zum Zitat Van Vollenhoven RF, Fleischmann R, Cohen S et al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367:508–519 PubMed Van Vollenhoven RF, Fleischmann R, Cohen S et al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367:508–519 PubMed
121.
Zurück zum Zitat Van Vollenhoven RF, Ostergaard M, Leirisalo-Repo M et al (2016) Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 75:52–58 PubMed Van Vollenhoven RF, Ostergaard M, Leirisalo-Repo M et al (2016) Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 75:52–58 PubMed
122.
Zurück zum Zitat Verschueren P, De Cock D, Corluy L et al (2017) Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1‑year results of CareRA, a randomised pragmatic open-label superiority trial. Ann Rheum Dis 76:511–520 PubMed Verschueren P, De Cock D, Corluy L et al (2017) Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1‑year results of CareRA, a randomised pragmatic open-label superiority trial. Ann Rheum Dis 76:511–520 PubMed
123.
Zurück zum Zitat Verschueren P, De Cock D, Corluy L et al (2015) Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis 74:27–34 PubMed Verschueren P, De Cock D, Corluy L et al (2015) Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis 74:27–34 PubMed
124.
Zurück zum Zitat Visser K, Van Der Heijde D (2009) Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 68:1094–1099 PubMed Visser K, Van Der Heijde D (2009) Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 68:1094–1099 PubMed
125.
Zurück zum Zitat Vital EM, Dass S, Buch MH et al (2015) An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. Ann Rheum Dis 74:1195–1201 PubMed Vital EM, Dass S, Buch MH et al (2015) An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. Ann Rheum Dis 74:1195–1201 PubMed
126.
Zurück zum Zitat Wailoo A, Hock ES, Stevenson M et al (2017) The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis. Health Technol Assess 21:1–258 PubMedPubMedCentral Wailoo A, Hock ES, Stevenson M et al (2017) The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis. Health Technol Assess 21:1–258 PubMedPubMedCentral
127.
Zurück zum Zitat Weinblatt ME, Fleischmann R, Van Vollenhoven RF et al (2015) Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Res Ther 17:325 PubMedPubMedCentral Weinblatt ME, Fleischmann R, Van Vollenhoven RF et al (2015) Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Res Ther 17:325 PubMedPubMedCentral
128.
Zurück zum Zitat Ziegler S, Huscher D, Karberg K et al (2010) Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997–2007: results from the National Database of the German Collaborative Arthritis Centres. Ann Rheum Dis 69:1803–1808 PubMed Ziegler S, Huscher D, Karberg K et al (2010) Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997–2007: results from the National Database of the German Collaborative Arthritis Centres. Ann Rheum Dis 69:1803–1808 PubMed
129.
Zurück zum Zitat Zink A, Manger B, Kaufmann J et al (2014) Evaluation of the RABBIT risk score for serious infections. Ann Rheum Dis 73:1673–1676 PubMed Zink A, Manger B, Kaufmann J et al (2014) Evaluation of the RABBIT risk score for serious infections. Ann Rheum Dis 73:1673–1676 PubMed
Metadaten
Titel
S2e-Leitlinie: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten
verfasst von
Prof. Dr. med. C. Fiehn
J. Holle
C. Iking-Konert
J. Leipe
C. Weseloh
M. Frerix
R. Alten
F. Behrens
C. Baerwald
J. Braun
H. Burkhardt
G. Burmester
J. Detert
M. Gaubitz
A. Gause
E. Gromnica-Ihle
H. Kellner
A. Krause
J. Kuipers
H.-M. Lorenz
U. Müller-Ladner
M. Nothacker
H. Nüsslein
A. Rubbert-Roth
M. Schneider
H. Schulze-Koops
S. Seitz
H. Sitter
C. Specker
H.-P. Tony
S. Wassenberg
J. Wollenhaupt
K. Krüger
Publikationsdatum
03.07.2018
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe Sonderheft 2/2018
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-018-0481-y

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.